Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinic ...

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1217027 (State ...

Financial Performance - The net loss for Q1 2024 was $35.0 million, or $(0.23) per share, compared to a net loss of $33.2 million, or $(0.22) per share, in Q1 2023[10]. - Total operating expenses for Q1 2024 were $38.9 million, compared to $37.0 million in Q1 2023[17]. - General and administrative expenses rose to $10.3 million in Q1 2024 from $9.4 million in Q1 2023, driven by increased legal fees and personnel costs[8]. - R&D expenses for Q1 2024 were $28.6 million, an increase from $27.6 million in Q1 2023, primarily due to higher clinical trial costs[7]. - The accumulated deficit as of March 31, 2024, was $641.0 million, up from $606.0 million at the end of 2023[16]. Funding and Cash Position - Erasca's pro forma cash, cash equivalents, and marketable securities are expected to be $334 million, which will fund operations into the second half of 2026[6]. - Erasca secured $45 million in private placement financing from high-quality investors, extending its cash runway into the second half of 2026[9]. Clinical Trials and Research - The company plans to initiate the pivotal SEACRAFT-2 trial evaluating naporafenib in Q2 2024, with a randomized readout expected in 2025[2]. - Initial Phase 1b combination data for SEACRAFT-1 is anticipated between Q2 and Q4 2024[9]. - The median overall survival (mOS) for naporafenib plus trametinib in patients with NRAS-mutant melanoma is reported as 13.0 to 14.1 months in a pooled analysis[3].

Erasca, Inc. (ERAS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 23rd:Fortuna Silver Mines Inc. (FSM) : This miner of precious and base metals has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 66.7% over the last 60 days.Fortuna’s shares gained 46.8% over the last three months compared with the S&P 500’s advance of 2.2%. The company possesses a Momentum Score  of A.Louisiana-Pacific Corporation (LPX) : This m ...

Erasca, Inc. (NASDAQ:ERAS) R&D Update Call and Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Jonathan Lim - Chairman, CEO & Co-founder Shannon Morris - Chief Medical Officer David Chacko - CFO & Chief Business Officer Conference Call Participants Anupam Rama - JP Morgan Michael Riad - Morgan Stanley Alec Stranahan - Bank of America Merrill Lynch Andres Maldonado - HC Wainwright & Co. Jonathan Miller - Evercore ISI Graig Suvannavejh - Mizuho Securities Chris Shibutani - Gold ...

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share. Erasca a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (Exact name of Registrant as specified in its Charter) | Delaware | | 83-1217027 | | --- | --- | --- | | (State or ...

Exhibit 99.1 Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS- 007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of Dec ...